紫杉醇洗脱支架治疗冠状动脉硬化性心脏病近期效果  

Short-term effect of paclitaxel-eluting stent in the treatment of coronary heart disease due to coronary arteriosclerosis

作　　者：万海燕[1] 朱国英[1] 王人彭[1] 苏唏[1] 彭剑[1] 宋丹[1] 陈国洪[1] 

机构地区：[1]武汉亚洲心脏病医院心内科,湖北武汉430022

出　　处：《第一军医大学学报》2005年第10期1299-1301,共3页Journal of First Military Medical University

摘　　要：目的评价紫杉醇洗脱支架(PES,商品名TAXUS)治疗冠状动脉硬化性心脏病患者的近期效果及安全性.方法对2003年7月至2004年11月在我院接受PES植入治疗的300例患者的即刻疗效和随访结果进行总结与分析.结果300例患者共处理350处病变,植入支架355枚,其中B2型以上复杂病变248处(70.9%),小管径支架(2.50～2.75 mm)94处(26.5%)、长支架(＞20 mm)130处(36.6%);术中未发生严重并发症,手术成功率100%.随访250例(83.3%),平均随访6个月(1～15个月),8例(2.7%)患者有心绞痛样发作,其中2例冠状动脉造影复查无支架再狭窄病变,1例于术后5个月发生心肌梗死,2例因非心源性因素死亡.结论PES治疗冠状动脉硬化性心脏病近期效果明显,且较为安全.Objective To evaluate the short-term safety and efficacy of paclitaxel-eluting stent （TAXUS stent, Boston Scientific） in the treatment of coronary heart disease （CHD） due to coronary arteriosclerosis. Methods From July 2003 to November 2004, 300 consecutive patients with CHD due to coronary arteriosclerosis were admitted for selective percutaneous coronary intervention （PCI） and paclitaxel-eluting stem implantation in the coronary arteries. The immediate effects after PCI and follow-up results were investigated. Results Altogether 350 lesions were treated and 355 paclitaxel-eluting stents implanted in the 300 cases. Of these lesions, 248 （70.9%） was complicated lesions of B2 type or worse, 94 （26.5%） smallcaliber stents （2.50-2.75 mm） and 130 （36.6%） long stents （〉20 mm） were implanted, without occurrence of severe intra-operative complications, follow-up study of 250 cases （83.3%） lasting for 1 to 15 months was conducted, and chest pain was reported in 8 cases, 2 of which underwent coronary artery angiography and no in-stent restenosis was found. One patient developed myocardial infarction 5 months after PC1, and 2 died for non-cardiogenic factors, Conclusion Paclitaxel-eluting stent implantation in patients undergoing PC1 is safe approach with good short-term efficacy.

关 键 词：药物洗脱支架 紫杉醇 经皮冠状动脉介人治疗 冠状动脉硬化性心脏病 

分 类 号：R541.4[医药卫生—心血管疾病]